From patients to discoveries

CRYOSTEM, a national cohort dedicated to the complications of Hematopoietic Stem Cell Transplantation (HSCT)


Biological resources

The patient-biobank duo:
the two pillars of novel precision medicine


Calls for project

CRYOSTEM supports international projects aimed to to better prevent, diagnose and treat the complications of HSCT


A collection unique in Europe

Launched within the framework of Investments for the Future by the National Research Agency (ANR), at the heart of the French Government’s Plan Cancer and supported by the National Cancer Institute (INCa), the CRYOSTEM’s project was initiated in 2011 under the auspices of the Francophone Society of Marrow Transplantations and Cellular Therapy (SFGM-TC) to accelerate research in the area of complications of Hematopoietic Stem Cell Transplantation (HSCT), previously called bone marrow transplantation.


Today the CRYOSTEM community offers academic and industrial research teams, a collection of more than 148 000 samples to fight life-threatening complications of HSCT.

Claire Fontenille
Project Manager CRYOSTEM

CRYOSTEM is a wonderful opportunity for researchers to better understand the biological mechanisms, to improve the prevention and the management of the complications of HSCT.

Dr. Claire Galambrun
Department of Pediatric Hematology,
The Timone Hospital

CRYOSTEM could play a significant role to predict the transplant toxicity.

Dr. Boris Calmels
Department of Hematology and Cell Therapy
Institut Paoli-Calmettes,
Founding Member of CRYOSTEM

The biological resource is the cornerstone of the CRYOSTEM process. It consists of biological samples and their associated clinical data collected on transplanted patients, which can be compared during the transplant various periods of life.

Géraldine Gallot
Biological Resources Center Representative,
The Nantes University Hospital (CHU)

In 2016 CRYOSTEM obtained the authorization to extend its collection to all the complications of HSCT.

Dr. Emilie Robert
Project Manager CRYOSTEM

What interests us it is being able to discriminate early before transplantation between patients who are going to benefit from the treatment.

Pr. Régis Peffault de Latour
Department of Hematology,
The Saint Louis Hospital,
Founding Member of CRYOSTEM

An informed patient is a better armed patient : at U2T, we use games to increase patients awareness of the HSCT complications.

Laurence Caymaris
Nurse Supervisor
Department of Onco-Hematology,
Institut Paoli-Calmettes


of transplanted patients in France

  • 4 436 Recipients
  • 1 840 Donors
  • 12 000 Sampling
  • 35 600 Samples (148 500 aliquots)



CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood. 2015 Mar 12;125(11):1830-9. doi: 10.1182/blood-2014-09-599159.

SOCIÉ G. ET AL., 2014

Current issues in chronic graft-versus-host disease. Blood. 2014 Jul 17;124(3):374-84. doi:10.1182/blood-2014-01-514752.

DONG S. ET AL., 2013

Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. Blood. 2013 Sep 5;122(10):1802-12. doi: 10.1182/blood-2013-02-482539.


Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood. 2012 Jun 14;119(24):5909-17. doi: 10.1182/blood-2011-12-397968.


HTC project

Spring 2017, CRYOSTEM accelerates and launches HTC project, an international research program to better understand the biology of HSCT* and to conquer its complications.

* HSCT standing for Hematopoietic Stem Cell Transplantation is the last resort for patients with blood cancer or severe immunodeficiency for whom no further therapeutic options are available: thanks to the donor’s healthy blood stem cells, they have the chance, so to speak, of starting again “from scratch”.


More information about CRYOSTEM

Contact Us